
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI Inc is positioned for significant growth, with projected revenue expected to increase at a compound annual growth rate (CAGR) of over 69% from FY26 through FY30 following the commercial launch of its DeepView System. The company's revised revenue guidance for FY26 projects research and development revenues of $18.5 million, a substantial increase from previous estimates, signaling enhanced market confidence and operational performance. Additionally, Spectral AI's licensing model is anticipated to generate recurring revenue with high margins, contributing to the stability and predictability of its growth trajectory in the MedTech sector.
Bears say
Spectral AI Inc has lowered its fiscal year 2025 revenue guidance for the BARDA contract to approximately $18.5 million, representing a 37.6% year-over-year decrease from prior expectations of $21.5 million, primarily due to the timing of contract work and impacts from a government shutdown. Furthermore, the company anticipates a decline in revenue for fiscal year 2026 compared to fiscal year 2025, indicating ongoing challenges in clinical and regulatory development timelines that could further negatively affect BARDA-related revenues. Additionally, while general and administrative expenses have decreased by 11.1% year-over-year to $4.0 million, the overall outlook remains pessimistic given the uncertainties surrounding funding and the operational effectiveness of the DeepView System.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares